The Cancer Drug Development Forum is an ad hoc representative of the Multi-Stakeholder Platform Advisory Group (MSP AG) under the Accelerating Clinical Trials in the EU (ACT EU).
The ACT EU initiative is run by the European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) to transform the EU into a region that supports clinical trial development and enables collaboration and innovation at all stages of the clinical research lifecycle. As part of its efforts, the ACT EU’s Multi-stakeholder platform (MSP) functions as a vehicle for clinical trials stakeholders and regulators to come together, voice their views and collaborate to improve the clinical trials environment for European patients and citizens.
The MSP enables dialogue with regulators through the creation of a MSP Advisory Group, in which the CDDF is selected to take part. The CDDF has embarked on this collaborative endeavor since January 2024 and continued its mission of accelerating the development and delivery of oncology drugs to patients.
